비교리스트

 카트 문의
시장보고서
상품코드
1320179

세계의 이중 특이성 항체 시장 : 제품 유형별, 용도별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Bispecific Antibody Market with COVID-19 Impact Analysis, By Product Type, By Application, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 258 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

이중 특이성 항체(Bispecific Antibody) 시장 규모는 2022년 6억 3,090만 달러였으며, 2023년부터 2030년까지 CAGR 8.3%로 추이하며 확대될 것으로 예상됩니다.

이중 특이성 항체 시장 - 시장 역학 :

암세계의 부담 증가와 효과적인 치료제가 없는 것이 이중 특이성 항체 시장의 성장을 가속할 것으로 예상됩니다.

암은 전 세계적으로 중대한 보건 문제이며 그 부담은 계속 증가하고 있습니다. 암 치료 및 관리 분야에서 진전이 있었지만 실행 가능한 치료법의 부족은 여전히 우려 사항입니다. 암 면역 치료에 대한 유망한 접근법 중 하나는 이중특이항체를 사용하는 것입니다. 세계보건기구에 따르면 암은 전 세계 주요 사망 원인으로, 2020년에 약 1,000만 명이 사망할 것으로 예상됩니다. 이중특이항체는 수많은 항원을 동시에 순차적으로 표적할 수 있다는 장점이 있으며 화학요법, 저분자 화합물, 체크포인트 억제제와 같은 면역조절 의약품과 함께 사용할 수 있습니다. 연구 개발 활동의 수가 증가하면 시장에 성장 기회를 제공 할 수 있습니다. 그러나 신약 개발과 관련된 높은 비용은 시장 성장을 방해합니다.

이중 특이성 항체 시장 - 주요 통찰 :

  • 이중 특이성 항체산업은 지속가능한 성장에 대한 의식이 높아짐에 따라 상당한 속도로 성장할 것으로 예측됩니다.
  • 제품 유형별로는 암이 2022년에 최대 시장 점유율을 나타냈습니다.
  • 적응증별로는 2022년에는 카투막소맙이 주요 유형이었습니다.
  • 지역별로는 북미가 2022년에 수익을 올리는 주요 시장이었습니다.

이중 특이성 항체 시장 - 세분화 분석 :

이중 특이성 항체 시장은 적응증, 제품 유형, 용도, 지역에 따라 세분화됩니다.

시장은 적응증에 따라 세가지 범주로 나뉩니다. 암, 염증성, 자가 면역 질환 등 입니다. 암이 시장을 독점하고 있습니다. 이중 특이성 항체는 암세포에 대한 신체의 면역반응을 강화할 가능성을 가진 면역치료제로서 큰 가능성을 나타내고 있습니다. 이중 특이성 항체는 암세포를 특이적으로 표적으로 하거나 면역세포를 보다 효과적으로 인식하여 암세포와 싸우도록 개변하기 위해 사용됩니다.

시장은 제품 유형에 따라 다양한 범주로 나뉩니다. 블리나투모맙(Blinatumomab), 카투막소맙(Catumaxomab), 듀리고투맙(Duligotumab) 등 입니다. 카투막소맙은 시장을 독점하고 있으며 예측 기간 동안에도 우위를 유지할 것으로 보입니다. 카투막소맙은 암 치료에 사용되어 온 이중 특이성 항체의 구체예입니다. 카투막소맙은 악성 복수(암세포가 복강 내에 축적되어 체액이 저류하는 병태)의 치료제으로서 개발된 3기능성 항체입니다.

시장은 용도에 따라 두가지 범주로 나뉩니다. 병원, 전문 클리닉 등 입니다. 병원은 암 치료의 최첨단에 있으며 이중 특이성 항체와 같은 최첨단 의약품을 제공하는데 중요한 역할을 하는 경우가 많습니다. 암 치료나 면역치료에 중점을 둔 전문 클리닉도 이중 특이성 항체의 투여에 관여하고 있을 가능성이 있습니다.

이중 특이성 항체 시장 - 지역적 통찰 :

지역적으로 이 시장은 북미, 남미, 유럽, 아시아 태평양, 중동 및 아프리카로 퍼져 있습니다. 이 지역은 비즈니스를 전개하는 국가에 따라 더 나뉩니다. 북미는 폐암, 전립선암, 유방암, 자궁경부암 등 암이 많기 때문에 이중 특이성 항체 시장을 독점하고 있습니다. 이러한 암은 이중 특이성 항체의 잠재적인 표적이며, 이 지역에서 이러한 치료법 수요를 견인하고 있습니다. 미국 국립암 연구소는 2020년에는 미국에서 180만 6,590명이 새롭게 암으로 진단되었으며 60만 6,520명이 암으로 사망할 것으로 예측했습니다. 게다가 유럽과 아시아 태평양은 표적 치료와 개인화 치료에 대한 수요 증가와 새로운 이중 특이성 항체 포맷 및 기술의 출현으로 이중 특이성 항체 시장 수요가 증가할 것으로 예측됩니다.

이중 특이성 항체 시장 - 경쟁 구도 :

이중 특이성 항체 시장은 매우 경쟁이 치열하며 각 기업은 시장 점유율과 약사 승인 취득을 목표로 하고 있습니다. 이중 특이성 항체의 개발은 제약 산업와 생명공학 산업에서 큰 관심을 끌고 있으며 시장 경쟁이 치열해지고 있습니다. 수많은 기업들이 연구개발에 자금을 제공하고 다양한 암 및 기타 질병에 초점을 맞춘 새로운 이중 특이성 항체 후보를 창출하고 있습니다. 이중 특이성 항체의 유용성을 지지하는 연구가 늘어남에 따라 다양한 유형의 암에 대한 이러한 치료법의 개발·이용에 대한 관심이 높아지고 있습니다. 일부 제약 회사와 생명 공학 회사는 자신의 이중 특이성 항체 지원자를 생산하는 연구 개발에 투자하고 있습니다. 이로 인해 효과적인 이중 특이성 항체치료을 시장에 투입하려고 경쟁하는 기업이 증가하고 있습니다. 각 회사는 이중 특이성 항체의 설계를 최적화하고, 제조 공정을 개선하고, 효과를 높이기 위한 병용 치료을 모색함으로써, 자사 제품의 차별화를 도모하고 있습니다. 예를 들어, Amgen과 Xencor, Inc.는 최근 암 면역치료와 염증 영역에서 신규 치료제의 개발과 상업화를 목적으로 한 연구·라이선스 계약을 체결했다고 발표했습니다. 이 공동 연구는 Amgen의 표적 탐색과 단백질 치료제의 능력과 Xencor의 XmAb 이중 특이성 기술 플랫폼을 융합시키는 것입니다.

목차

제1장 이중 특이성 항체 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 이중 특이성 항체 주요 시장 동향

  • 이중 특이성 항체 시장 성장 촉진 요인
  • 이중 특이성 항체 시장 성장 억제 요인
  • 이중 특이성 항체 시장 기회
  • 이중 특이성 항체 시장 향후 동향

제4장 이중 특이성 항체 산업 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 프레임워크 분석

제5장 이중 특이성 항체 시장 : COVID-19 영향 분석

  • COVID-19 이전 영향 분석
  • COVID-19 이후 영향 분석

제6장 이중 특이성 항체 시장 상황

  • 이중 특이성 항체 시장 점유율 분석(2022년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신흥 기업 분석

제7장 이중 특이성 항체 시장 - 제품 유형별

  • 개요
    • 제품 유형별 부문 점유율 분석
    • 블리나투모맙(Blinatumomab)
    • 카투막소맙(Catumaxomab)
    • 듀리고투맙(Duligotumab)
    • 기타

제8장 이중 특이성 항체 시장 - 용도별

  • 개요
    • 용도별 부문 점유율 분석
    • 병원
    • 전문 클리닉
    • 기타

제9장 이중 특이성 항체 시장 - 적응증별

  • 개요
    • 적응증별 부문 점유율 분석
    • 암
    • 염증성·자가면역질환
    • 기타

제10장 이중 특이성 항체 시장 - 지역별

  • 소개
  • 북미
    • 개요
    • 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아 태평양(APAC)
    • 개요
    • 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 남미
    • 개요
    • 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석-이중 특이성 항체 산업

  • 경쟁 대시보드
  • 기업 개요
    • Genmab
    • Merus
    • Chugai Pharmaceutical
    • Ablynx
    • Genentech
    • Jounce Therapeutics
    • Affimed Therapeutics
    • Eli Lilly
    • AstraZeneca(MedImmune)
    • Neovii Biotech
    • Pieris
    • Adimab
    • Immunomedics
    • Roche
    • Amgen
    • Sanofi
    • Emergent BioSolutions
    • NovImmune SA
    • Regeneron Pharmaceuticals
    • EMD Serono
    • OncoMed Pharmaceuticals
    • MacroGenicsC

제12장 애널리스트의 전방위 전망

LYJ 23.08.21

REPORT HIGHLIGHT

Bispecific Antibody Market size was valued at USD 630.9 Million in 2022, expanding at a CAGR of 8.3% from 2023 to 2030.

Bispecific antibodies aim to treat multi-layered, complex diseases by engaging two disease targets with one molecule. They are synthetic hybrid molecules having two separate binding domains that target two unique antigens, as opposed to natural antibodies, which have two targeting arms that attach to the same target antigen. Bispecific antibodies are typically not found in nature but are instead created using recombinant DNA techniques or cell fusion. By focusing on two distinct disease pathways, bispecific antibodies have the potential to increase therapeutic efficacy in the treatment of complicated human diseases.

Bispecific Antibody Market- Market Dynamics:

The rising global burden of cancer and the unavailability of effective curing drugs possess are expected to propel the growth of the Bispecific Antibody Market.

Cancer is a significant global health challenge, and its burden continues to rise. While advances in cancer treatment and care have been made, the lack of viable curative treatments remains a concern. One promising approach to cancer immunotherapy is the use of Bispecific Antibodies. According to the world health organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Bispecific antibodies have the benefit of being able to target numerous antigens simultaneously and sequentially, and they can be employed in conjunction with chemotherapy, small compounds, and immunomodulatory medicines like checkpoint inhibitors. An increase in the number of research and development activities can provide growth opportunities for the market. However, the High cost associated with drug development hampers the market growth.

Bispecific Antibody Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Bispecific Antibody market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2023-2030)
  • The Bispecific Antibody industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on Product Type segmentation, Cancer was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Catumaxomab was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Bispecific Antibody Market- Segmentation Analysis:

The Global Bispecific Antibody Market is segmented on the basis of Indication, Product Type, Application, and Region.

The market is divided into three categories based on Indication: Cancer, Inflammatory & Autoimmune Disorders, and Others. Cancer dominates the market. Bispecific antibodies have shown tremendous potential as immunotherapeutic medicines with the potential to enhance the body's immune response against cancer cells. They can be employed to specifically target cancer cells or modify immune cells to more effectively recognize and battle cancer cells.

The market is divided into two categories based on Product Type: Blinatumomab, Catumaxomab, Duligotumab, and Others. Catumaxomab dominates the market and is likely to maintain its dominance during the forecast period. Catumaxomab is a specific example of a bispecific antibody that has been used in cancer treatment. It is a trifunctional antibody that was developed for the treatment of malignant ascites, a condition where cancerous cells accumulate in the abdominal cavity and lead to fluid buildup.

The market is divided into two categories based on application: Hospitals, Specialty Clinics, and Others. Hospitals are on the cutting edge of cancer care and frequently play a crucial part in delivering cutting-edge medicines like bispecific antibodies. Specialty clinics that focus on cancer care or immunotherapy may also be involved in administering bispecific antibodies.

Bispecific Antibody Market- Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America dominates the Bispecific Antibody market due to the highest numbers of several cancers such as lung cancer, prostate cancer, breast cancer, and cervical cancer. These cancers are potential targets for bi-specific antibodies, driving the demand for such therapies in the region. National cancer institute predicted that in 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. Furthermore, Europe and Asia Pacific are projected to demand for Bispecific Antibody Market, due to the growing demand for targeted and personalized therapies and the emergence of novel bispecific antibody formats and technologies.

Bispecific Antibody Market- Competitive Landscape:

Bispecific antibody markets are highly competitive, with businesses aiming for market share and regulatory approvals for their goods. Bispecific antibody development has attracted significant interest from the pharmaceutical and biotechnology industries, raising market competition. Numerous companies have been funding research and development to create novel bispecific antibody candidates that focus on various cancers and other diseases. As more research supports the benefits of Bispecific antibodies, there is a growing interest in developing and utilizing these therapies for various types of cancer. Several pharmaceutical companies and biotechnology firms are investing in research and development to create their own Bispecific antibody applicants. This has led to an increase in the number of companies competing to bring effective Bispecific Antibody therapies to the market. Companies are striving to differentiate their products by optimizing the design of Bispecific Antibody, improving manufacturing processes, and exploring combination therapies to enhance their effectiveness. For Instance, Amgen and Xencor, Inc. announced nowadays that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb bispecific technology platform.

Recent Developments:

Dec. 19, 2022, Biogen Inc. announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the company's long-standing collaboration on antibodies targeting CD20.

Key features of the study:

  • This proposed research study on the Bispecific Antibody market provides market size (US$ Million), compound annual growth rate (CAGR %), and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Bispecific Antibody market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Bispecific Antibody market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Bispecific Antibody market
  • Impact of COVID-19 on Bispecific Antibody market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Bispecific Antibody market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Bispecific Antibody market, we have also included competitive landscape and key innovator analysis for the Bispecific Antibody market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Bispecific Antibody market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Bispecific Antibody market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BISPECIFIC ANTIBODY MARKET KEY PLAYERS

  • Genmab
  • Merus
  • Chugai Pharmaceutical
  • Ablynx
  • Genentech
  • Jounce Therapeutics
  • Affimed Therapeutics
  • Eli Lilly
  • AstraZeneca (MedImmune)
  • Neovii Biotech
  • Pieris
  • Adimab
  • Immunomedics
  • Roche
  • Amgen
  • Sanofi
  • Emergent BioSolutions
  • NovImmune SA
  • Regeneron Pharmaceuticals
  • EMD Serono
  • OncoMed Pharmaceuticals
  • MacroGenicsC

GLOBAL BISPECIFIC ANTIBODY MARKET, BY INDICATION

  • Cancer
  • Inflammatory & Autoimmune Disorder
  • Others

GLOBAL BISPECIFIC ANTIBODY MARKET, BY PRODUCT TYPE

  • Blinatumomab
  • Catumaxomab
  • Duligotumab
  • Others

GLOBAL BISPECIFIC ANTIBODY MARKET, BY END-USER

  • Hospital
  • Specialty Clinics
  • Others

GLOBAL BISPECIFIC ANTIBODY MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bispecific Antibody Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bispecific Antibody Market Snippet by Product Type
    • 2.1.2. Bispecific Antibody Market Snippet by Application
    • 2.1.3. Bispecific Antibody Market Snippet by Indication
    • 2.1.4. Bispecific Antibody Market Snippet by Country
    • 2.1.5. Bispecific Antibody Market Snippet by Region
  • 2.2. Competitive Insights

3. Bispecific Antibody Key Market Trends

  • 3.1. Bispecific Antibody Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bispecific Antibody Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bispecific Antibody Market Opportunities
  • 3.4. Bispecific Antibody Market Future Trends

4. Bispecific Antibody Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bispecific Antibody Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bispecific Antibody Market Landscape

  • 6.1. Bispecific Antibody Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bispecific Antibody Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2022 & 2030 (%)
    • 7.1.2. Blinatumomab
    • 7.1.3. Catumaxomab
    • 7.1.4. Duligotumab
    • 7.1.5. Others

8. Bispecific Antibody Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 8.1.2. Hospital
    • 8.1.3. Specialty Clinics
    • 8.1.4. Others

9. Bispecific Antibody Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 9.1.2. Cancer
    • 9.1.3. Inflammatory & Autoimmune Disorder
    • 9.1.4. Others

10. Bispecific Antibody Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bispecific Antibody Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bispecific Antibody Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bispecific Antibody Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bispecific Antibody Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bispecific Antibody Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Bispecific Antibody Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Genmab
    • 11.2.2. Merus
    • 11.2.3. Chugai Pharmaceutical
    • 11.2.4. Ablynx
    • 11.2.5. Genentech
    • 11.2.6. Jounce Therapeutics
    • 11.2.7. Affimed Therapeutics
    • 11.2.8. Eli Lilly
    • 11.2.9. AstraZeneca (MedImmune)
    • 11.2.10. Neovii Biotech
    • 11.2.11. Pieris
    • 11.2.12. Adimab
    • 11.2.13. Immunomedics
    • 11.2.14. Roche
    • 11.2.15. Amgen
    • 11.2.16. Sanofi
    • 11.2.17. Emergent BioSolutions
    • 11.2.18. NovImmune SA
    • 11.2.19. Regeneron Pharmaceuticals
    • 11.2.20. EMD Serono
    • 11.2.21. OncoMed Pharmaceuticals
    • 11.2.22. MacroGenicsC

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제